产品
编 号：F490473
分子式：C20H16BCl2NO3
分子量：400.06
分子式：C20H16BCl2NO3
分子量：400.06
产品类型
规格
价格
是否有货
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 872044-70-7
产品详情
生物活性：
AN0128 is a boron-containing antibacterial and anti-inflammatory agent. AN0128 against S. aureus, S. epidermidis, P. acnes, B. subtilis with minimum inhibitory concentration (MIC) values of 1, 0.5, 0.3, 1 μg/mL. AN0128 can be used for the research of periodontal disease and cutaneous diseases.
体内研究：
AN0128 (1%, 5%; daily topical daub for 7 days) significantly reduces the formation of an inflammatory infiltrate and reduces bone loss.Animal Model:Experimental periodontitis in twelve-week-old male Sprague-Dawley rats (weighing from 275 to 300 g each)
Dosage:1% AN0128 in 40% Transcutol P, 40% PBS, and 20% ethanol vehicle
Administration:Daily topical daub for 7 days
Result:Similar to Ketorolac, resulting 50% and 35% increase in bone area and bone volume respectively, and 38%, 42% decrease in bone loss and inflammation respectively.
Animal Model:Experimental periodontitis in twelve-week-old male Sprague-Dawley rats (weighing from 275 to 300 g each)
Dosage:5% with Total toothpaste
Administration:Applied daily via a cotton-tip applicator. for 7 days
Result:Had more effect than Total toothpaste, resulting in a 33% increase in bone volume, and a 47% decrease in bone loss.
体外研究：
AN0128 (compound 2g; 10 μM; 24-48 hours) shows strong inhibition of the release of pro-inflammatory cytokines (TNF-α, IL-1β) but no inhibition of IFN-γ or IL-4 release in human peripheral blood mononuclear cells (PBMCs).
AN0128 is a boron-containing antibacterial and anti-inflammatory agent. AN0128 against S. aureus, S. epidermidis, P. acnes, B. subtilis with minimum inhibitory concentration (MIC) values of 1, 0.5, 0.3, 1 μg/mL. AN0128 can be used for the research of periodontal disease and cutaneous diseases.
体内研究：
AN0128 (1%, 5%; daily topical daub for 7 days) significantly reduces the formation of an inflammatory infiltrate and reduces bone loss.Animal Model:Experimental periodontitis in twelve-week-old male Sprague-Dawley rats (weighing from 275 to 300 g each)
Dosage:1% AN0128 in 40% Transcutol P, 40% PBS, and 20% ethanol vehicle
Administration:Daily topical daub for 7 days
Result:Similar to Ketorolac, resulting 50% and 35% increase in bone area and bone volume respectively, and 38%, 42% decrease in bone loss and inflammation respectively.
Animal Model:Experimental periodontitis in twelve-week-old male Sprague-Dawley rats (weighing from 275 to 300 g each)
Dosage:5% with Total toothpaste
Administration:Applied daily via a cotton-tip applicator. for 7 days
Result:Had more effect than Total toothpaste, resulting in a 33% increase in bone volume, and a 47% decrease in bone loss.
体外研究：
AN0128 (compound 2g; 10 μM; 24-48 hours) shows strong inhibition of the release of pro-inflammatory cytokines (TNF-α, IL-1β) but no inhibition of IFN-γ or IL-4 release in human peripheral blood mononuclear cells (PBMCs).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备